ArticleBlood pressure monitoring2025
Association of phenotypic age acceleration with the risk of all-cause and cardiovascular disease-related mortality in patients with hypertension.
Article in Blood pressure monitoring, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Phenotypic age acceleration and omega-6/omega-3 PUFA ratio in dynamic atrial fibrillation-heart failure transitions: a multistate analysis.The journal of nutrition, health & aging · 2026Article
- Predictive Value of Biological Age for All-Cause Mortality in Patients with COPD.International journal of chronic obstructive pulmonary disease · 2026Article
- Phenotypic Age Acceleration as a Mediator in Thyroid Hormone-Related Cardiovascular Risk Among the Elderly.Cardiology research and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the associations between phenotypic age acceleration (PhenoAgeAccel) and all-cause/cardiovascular disease (CVD)-related mortality in hypertensive patients.
methodsWe analyzed data from 14 352 hypertensive adults (≥20 years) in the National Health and Nutrition Examination Survey 1999-2010. PhenoAge was calculated using chronological age and nine biomarkers (albumin, creatinine, glucose, C-reactive protein, lymphocyte%, mean cell volume, red blood cell distribution width, alkaline phosphatase, and white blood cell count). PhenoAgeAccel was derived as residuals from linear regression of PhenoAge on chronological age. Participants were stratified by PhenoAge [<46.6792 (792-64.774 (T1-T2), ≥64.774 (≥T2)] and PhenoAgeAccel [<-4.3382 (382-0.9896 (T1-T2), ≥0.9896 (≥T2)] tertiles. Cox proportional hazards models assessed mortality risks.
resultsIncreased all-cause mortality was observed in hypertensive patients with PhenoAge in T1-T2 group [hazards ratio = 4.38, 95% confidence interval (CI): 3.79-5.06] and greater than or equal to T2 (hazards ratio = 14.22, 95% CI: 12.32-16.43). Significant association between PhenoAgeAccel greater than or equal to T2 and increased risk of all-cause mortality in hypertensive patients (hazards ratio = 1.41, 95% CI: 1.29-1.55) was identified. PhenoAge of T1-T2 (hazards ratio = 5.15, 95% CI: 3.86-6.86) and greater than or equal to T2 (hazards ratio = 20.20, 95% CI: 14.98-27.26) were related to increased CVD-related mortality in hypertensive patients. Increased risk of CVD-related mortality was identified in hypertensive patients with PhenoAgeAccel greater than or equal to T2 (hazards ratio = 1.35, 95% CI: 1.17-1.56).
conclusionElevated PhenoAge and PhenoAgeAccel significantly predict higher all-cause and CVD mortality in hypertension, supporting clinical risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.